Introduction
Piper cubeba is an important plant belonging to the Piperaceae family,c ommonly known as cubeb or Java pepper,a nd it is cultivated for its fruit ande ssential oils. It is grown in Indonesia, mainly in the Java and Sumatra islands, andi ns outhern India. [1] Piper cubeba is used as as pice in many countries and is economically important. [1, 2] The bioactive compoundsf rom Piper cubeba have been of great value in the discovery of new therapeutic agents to treat ailments associated with inflammatory problems, renal disorders, gonorrhea, syphilis, abdominal pain, enteritis, and asthma. [3, 4] 
Lignans in General
Analysis of the literaturei ndicates that 24 lignans have so far been reported from extracts of P. cubeba. [1, 3, [5] [6] [7] Lignans are secondary metabolites produced by plants that have aw ide range of biological properties which are intrinsically related to their stereochemistry. [5, 6, 8, 9] This variety is relatedt ot he diversity of carbon skeletons that these classes of natural products present in plants. [10] The denomination of the lignan class of compounds was created in 1936 by Haworth to describe a group of dimericp henylpropanoidsa nd, therefore, originated from aw ide variety of lignans. There are eight subclasses of lignans, including dibenzylbutane, dibenzylbutyrolactol, dibenzylbutyrolactone, furan, furofuran, aryltetralin, arylnaphthalene, and dibenzocyclooctadiene ( Figure 1 ). [10] [11] [12] Lignans are present mainly in plants but can also be found in mammals and are produced by the action of intestinal bacteria from food lignans (matairesinol, secoisolariciresinol, pinoresinol, sesamin, lariciresinol, syringaresinol, 7-hydroxytatairesinol, and artigenina) found in flax seeds, fruits, and vegetables. [13] [14] [15] [16] [17] [18] In Linum, Anthriscus,a nd Podophyllum plants, matairesinol is also converted into hinokinin, yatein, or podophyllotoxin throughm ultiple biosynthetic pathways, even though all relevant enzymes have not yet been identified. [19] Enterolactone and enterodiol have been cited as providing protection against cardiovascular disease, diabetes, and cancer. [18] These and other lignans also have antioxidant activity [20] and reduce oxidative stress. Lignans with anticancer activity behavei nm etabolic pathways, however,t hrough the inductiono fc ell death by apoptosis. [21] [22] [23] [24] Of the Piper cubeba lignans,s everal classes can be isolated from roots, rhizomes, stems,l eaves, seeds (Figure 2 ), and Lignans are al arge class of natural products that have been isolated from many plants.They revealdiverse biological activities, especially antiviral and antitumorp roperties. From Piper cubeba,l ignans of several classes can be isolatedf rom the roots, rhizomes, stems,leaves,seeds, and fruits.Among its various chemical constituents, (À)-cubebin and (À)-hinokinin are found in significant quantities.A lthough they have been known for some time, during the last few decades their biological properties have been studied by severalr esearch groups.
The cubebins have been identified asalactol monomer and dimers as am ixture of diastereoisomers. Recently,t heir structural characterization and the synthesis of the possible structures have led to the correction of some earlier structural proposals. This review describes the more recent developmentsi n the study of the medicinala ttributeso fc ubebin and hinokinin extracted from Piper cubeba and the synthesis and biological testingo fs ome analogues. Figure 1 . General classeso fl ignans. [10] fruits. [1, 25] Recent studies aimed at investigating the biological activities of crude fruit extracts [26, 27] have been related to biological properties discovered in lignans. [28] Some interesting biological activities of lignans extracted from P. cubeba have been reported, and these lignans could potentially be developed as new drugs. [1, 6, 25, 29] Thus, the aim of this review is to describe the medicinal attributes and current developments of the structurally similarl ignans hinokinin and cubebin, which possess ab road range of biological activities and are major componentsoft he fruits of P. cubeba. 
(À)-Cubebin
An important dibenzylbutyrolactone lignan is (À)-cubebin (1); the lactol structure and stereochemistry of cubebin (Figure 3 ), ac onstituent of cubeb fruits (Piper cubeba), wase lucidated by Batterbee. [30] (À)-Cubebin (1)h as been isolated from ac rude hexane extract of the leaves of Zanthoxylumn aranjillo.
[31] The Piper nigrum crude ethanole xtract presents phytochemical compounds, [32] althought he crude ethanole xtract of P. cubeba has higher antioxidanta ctivity than the extracts from other Piper species. [27] (À)-Cubebin is am ajor component of Piper cubeba seeds. [33] During the last decades, interesting new biological properties of this compound have been discovered.
Synthesis

Biosynthetic Pathways
In 2017, Pissurno and Laurentiz proposed biosynthetic pathways for lignans containing oxygen atoms at the C-9 and C-9' Piper cubeba seeds. [29] Figure 3. (À)-Cubebin structure as amixture of epimers at C-9'. [33] ChemistryOpen 2018, 7,180 -191 www.chemistryopen.org 2018 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim positions (Scheme 1). The biosynthesis of these lignans is initiated by enantioselective dimerization of two units of coniferyl alcohol (4)t op rovide pinoresinol( 5), which is reduced to lariciresinol (6)t op roduce secoisolariciresinol (7) . Compound 7 is then oxidized by secoisolariciresinol dehydrogenase to produce matairesinol (8) . Cubebin (9)i so btained through condensation of the hydroxy and methoxy groups on the aromatic rings thus to produce the methylenodioxyg roup. [11] 3.1.2. Structure Determinationand Chemical Synthesis 3.1.2.1. Semisynthetic Derivatives of (À)-Cubebin Semisynthetic derivatives of (À)-cubebin (1)h ave been obtained by transformationo fn atural compound 1 by using the reagents and conditions indicated in Scheme 2. [2, 8, 29, 30, [34] [35] [36] In 2005, De Souza et al. developed novel therapeutic compounds for the treatment of Chagasd isease and studied their biological activity against the amastigote formso fl ignans 1, 10, 11,a nd 12 (Scheme 2). [35] Of the (À)-cubebind erivatives tested, the most promising was (À)-hinokinin (12) . [35] In 2016, Rajalekshmi et al. [2] isolated al ignan lactol then known as (À)-cubebinf rom Piper cubeba seeds and prepared severalderivatives by modifying the lactol ring to obtain different types of functionalities. The authors tested their compounds for in vitro anticancer activity against six human cancer cell lines (i.e. A549, K562, SiHa, KB, HCT116, and HT29) by using a3 -(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.Inthat study,cell death occurredt hrough necrosis or apoptosis, and morphological analysis was performed and two cell lines (A549 and KB) were selected. Comparisonw ith literature values obtained for podophyllotoxin and etoposide that were then used as chemotherapeutic agent showed that these lignans possessed promisingi nvitro anticancer activity.I nt he study,t he cells were treated with (À)-hinokinin and amide derivatives 15 (Scheme 3), which showedb etter results than the parent compounds, cubebin/hinokinin, in severaloft he tested cell lines. [2] 
Assignment of Structure and Absolute Stereochemistry of (À)-Cubebin and Some Bicubebins
In 1969, the first synthesis of cubebin was described [30] on the basis of the structure and absolute stereochemistry proposed by Haworth, [37] Mameli, [38] and Lin. [39] Generally,c ubebin, whether obtained from an atural source or by synthesis, hasb een assumed to be am ixture of two 8,8'-trans-lactol epimers at C-9 ( Figure 4 ) [6, [40] [41] [42] [43] [44] [45] with the relative configuration at C-9 not defined. [33, 35] In 2006, De Pascoli et al. published very informativew ork [46] concerning the configurational analysis of cubebins and characterization of the first bicubebin. Complex mixtureso fc ubebins obtained from an ethanol extract of the tubercula of Scheme1.Proposed biosynthetic pathways for cubebin. [11, 74] Scheme2.Semisynthetic derivatives of (À)-cubebin. Reagents and conditions:a)Ac 2 O, pyridine, RT,24h;b)NaH,B nBr,THF,RT, 24 h; c) PCC, CH 2 Cl 2 , RT,1 2h;d)HNO 3 ,2h, À108 C. [8, 35] Scheme3.Compounds 15 a-i as amide derivatives of (À)-hinokinin. [2] ChemistryOpen 2018, 7,180 -191 www.chemistryopen.org 2018 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim A. pubescens and an acetone extract from the roots of A. lagesiana were subjected to preparative chromatography followed by semipreparative HPLC to obtain four different compounds. Their structures were determinedb ys pectroscopicm ethods, including 1 HNMR, 13 CNMR, UV,a nd IR spectroscopy.O nt he basis of previousr eports on cubebin, [6, 40, 41, 47] the structure of cis-cubebin( 1)w as suggested ( Figure 4 ) after careful analysis of On the basis of these data the authors suggested two hypotheses:t here were two epimers (at C-9 and/or C-8) in equilibrium and the cubebin speciese xisted in equilibrium due to the factt hat lactolsc an undergo ring opening and closing in solution.
In another approach to try to confirmt he relative configurations and the absolute configurations of compounds 17, 18, and 19,the authors transformed these compounds into hinokinins that hada lready been reported. [30, 48] The results confirmed that anomers 18 a and 19 a had the same configuration [i.e. (8R,8'R)] at the same chiral centers.
Finally,a nother compound was isolateda nd its structure was elucidated by using 1 HNMR and 13 CNMR spectroscopy, HMQC,a nd ESI-MS experiments by comparing all of the NMR spectroscopy data obtainedf or this compound with those for 18 and 19,i na ddition to thed ata obtained by 1D NOESY experiments. On the basis of the results, the stereochemistry was assigned as the dimer ( (20) (namedb icubebin A), and this compound was the first bicubebin described. Compound 20 could be formed through dehydration of two cubebin units ( Figure 5 ).
More recently,D avidson et al. [49] explored the synthesis of cubebin, as outlined in Scheme 4. Stereoselective allylation of the enolateo fp iperonyl acetic acid derivative 21 having an Evans chiral auxiliary afforded compound 22.T his was dihydroxylated to form 23 that cyclized to form lactone 24.R eduction to the triola nd oxidative cleavage produced the hydroxy aldehydet hat spontaneously cyclized to form the corresponding lactol.M ild oxidation produced lactone 25 with the carbonyl positioned such that stereoselective transalkylation of its enolatew ith piperonyl bromide produced hinokinin (12) , which was reduced to cubebin (1)w ith diisobutylaluminum hydride (DIBAL-H).
Ad ehydration reaction using copper reagents produced the dimers through an acetal linkage ( Figure 6 ).
The unsymmetrical dimer (À)-bicubebin A(20)w as previously described by De Pascoli et al. [46] but the other two symmetrical bicubebins, that is,b icubebinB (26)a nd bicubebin C( 27), had not previously been reported. Comparisono ft he spectro- ' . Figure 5 . Structure of bicubebin A. [45] Scheme4.Summary of the synthesis of (À)-cubebin.
[49] Figure 6 . Bicubebins obtained by dimerization of (À)-cubebin. [48] ChemistryOpen 2018, 7,180 -191 www.chemistryopen.org 2018 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim scopic datao fs ynthetic optically pure bicubebinA with those describedi nt he literature [46] confirmed the absolutes tereochemistry as (8R,9S,
Further, the authors comparedt he analytical data for (À)-bicubebin B( 26)w ith those reported for (À)-cis -cubebin (17), which had been isolated along with (À)-bicubebin A, and they found that the 1 HNMR and 13 CNMR spectroscopy data and opticalrotationvalues overlapped.
Ta king these results together,D avidson et al. [49] believed that the structure proposed in the literature as cis-cubebinw as in fact as ymmetrical dimer and not the lactol reported until then. To confirm this interpretation, racemic cis-cubebin was prepared (Scheme 5).
The synthesis of racemic supposed cis-cubebin (Scheme 5) started from picolinylacetyl chloride (28) , which was treated with allyl amine 29 in an acid-catalyzed acyl-Claisen rearrangement to form morpholinide 30 stereoselectively.H aving all of the stereochemistryd efined, simple transformations produced cis-cubebin(31)a samixture of ketols.
In addition, the spectroscopic data for compound 31 obtained through this stereoselective synthesis were very different from those described in the literature for cis-cubebin by De Pascolie tal. [46] Thus, this result confirmed that the structure describedi nt he literature until then as cis-cubebinw as not lactol 17 (Figure 4 ), but ad imer (À)-[bicubebin B] (26) (Figure 6 ).
Biological Activities of (À)-Cubebin
Although (À)-cubebin has been knownf or over 100 years, during the last decades this molecule has attracted the attention of several research groups because of the interesting biological properties attributed to the extract of the fruits of P. cubeba,i nw hich it occurs to the extent of 3%.
[1]
Cytotoxic Activity
The cytotoxicity of cubebin has been investigated by several authors against different cancer lines:A 549 (human lung adenocarcinoma), KB (human nasopharyngeal carcinoma), K562 (human chronic myeloid leukemia), SiHa (human cervical carcinoma), and HCT116 (human colon carcinoma) and HT29 (human adenocarcionoma). [2] (À)-Cubebin possesses very good activity against the A549, K562, and KB cell lines, with median inhibitory concentration (IC 50 )v alues below 9 mm,b ut it is less effective against other cell lines. [2] In human colon adenocarcinoma cells (HT29) treated with (À)-cubebin [33] at concentrationsu pt o2 8 mm,c ytotoxicity,m utagenicity,a poptotic cell death, and enhanced growth were not observed. (À)-Cubebinw as cytotoxic at 280 mm and decreased cell viability by approximately 50 %a fter treatment for 24 h. Lower concentrations caused no apparent damaging effects, but caution is neededu pon using (À)-cubebin at high concentrations. [33] 
Anti-inflammatory Activity
Inflammation can be caused by cancer development, and for this reason, nowadays, the anti-inflammatory activity of natural compounds is broadly studied. [34] (À)-Cubebin, isolated from the crude hexane extract of the leaves of Z. Naranjillo, [31] showeds ignificant anti-inflammatory activity in paw edemai nduced by carrageenani nr ats;i ts howed5 3% inhibition of edema. In the evaluation of analgesic activityb yu sing a0 .6 % acetic acid induced abdominal contortion model, (À)-cubebin presented 50 %i nhibition of animal contortionsr elative to the controlgroup. [31] In 2013, Perazzoe tal. studied the anti-inflammatory effect of P. cubeba L. seed extract (PCE) and its fractions through in vivo assays on rat paw carrageenan-induced edema, andt he median effective dose (ED 50 )a nd on-ear edemai nduced by crotono il were investigated. [3] This study showed that all fractions of PCE obtained with different organic solvents showed different degrees of inhibition of carrageenan-induced edema. Moreover,t he methylene chloride fraction showedt he best activity,w hichi ndicatedt hat the active compounds were concentrated in this fraction.T hese compounds were probably cubebins that were previously described as anti-inflammatory agents. [3, 31] In 2013, Mukhija and Sundriyal reported that the lignan isolated from the crude hexane extract of the leaves of Zanthoxylum naranjillo showed significant anti-inflammatory activity in paw edema induced by carrageenan in rats but did not provide as ignificant reduction in cell migration for the acute carrageenan-induced inflammatory reaction in the peritoneal cavity of rats. Furthermore, this lignan significantly reduced edemai nduced by prostaglandin PGE2 and the number of writhings( amount of discomfort) induced by both acetic acid and PGI2 in mice. The mechanism of action of (À)-cubebin is similart ot hat observed for most nonsteroidal drugs. [50] 3.2.3. Antiparasitic Activity (À)-Cubebin showedi nteresting activity against Trypanosoma cruzi,t he parasite responsible for Chagas disease, an eglected protozoan diseaset hat affects some1 0million people in Latin America. [7, 34, 35, 51, 52] Scheme5.Synthesis of racemic cis-cubebin. In 2005, De Souza et al. reported the trypanocidal activity of (À)-cubebin and its semisynthetic derivatives against free amastigote forms of T. cruzi. [35] In 2010, Esperandim et al. [34] evaluated the trypanocidal activity of cubebinsa nd hinokinins in vivo during the chronic Chagas disease phase. In that study,A lbino BALB/c mice were divided into groups accordingt ot he drug administration type [oral (p.o.) and intraperitoneal (i.p.)] and dosage( 20 and 50 mg kg À1 ). The groups included an egative control, which was separated (inoculated with trypomastigotes) and treated with the solvent used to preparet he solutions;apositive group, which was treated with benznidazole;a nd an negative group. In all cases, treatmentw as initiated 90 days after infection and parasitism reduction was assessed by b-galactosidase quantification. Relative to the group treated with benznidazole, the group treated with lignans resulted in ag reater reduction in parasitism in all organs evaluated. Oral treatment showed more effective results. The data suggested that cubebins and their analogues could be considered as potential compounds for the development of new drugs against Chagasdisease. [34] In 2013, Esperadim et al. conducted an in vivo study to verify cubebin activity against T. cruzi. In this study,B ALB/c mice were inoculated with 2 10 4 trypomastigote forms 48 h before treatment. The mice were divided into six groups during the acute phase of T. cruzi infection:n egative control (5 %i .p. injection with 5% DMSO, 2.5 %T ween, 5% ethanol), positive control (benznidazole, 20 and 50 mg kg À1 p.o.), and cubebin (20 and 50 mg kg À1 p.o.). The animalsw ith acute parasitaemia were investigated by morphometric tissue analysis. There was as ignificant parasitaemia reductioni na nimalst reated with cubebin compared to the negative control. [53] 
Antitumor Activity
Carcinogenesis is acomplex process that occurs by the interaction of ac arcinogenic agent( or oncogenic agent)w ith genes that changes cell characteristics andr esultsi nt he loss of control of cell divisiona nd culminates in the uncontrolled growth of neoplastic cells. [6] In 2015, Graidist et al. determined the cytotoxic effect of crude P. cubeba extracts on normalf ibroblast( L929), normal breast (MCF-12A), and three breast cancerc ell lines (i.e. MCF-7, MDA-MB-468, and MDA-MB 231). Fraction Cw as furthers eparated into seven fractions, CA to CG. The 1 HNMR spectrum showedt hat fraction CE consisted mainly of long-chain hydrocarbons. [54] JimØnez-Arellanes et al. recently reported as tudy on the action of (À)-cubebin extracted from Aristolochia elegans Rhizomes against Mycberculosis H37Rv.A ne ncouraging minimum inhibitory concentrationo f5 0mgmL À1 was found, and the authors concluded that this compound could be used as al ead for the synthesis of derivatives with greater antimicrobial action. [55] 
Erectile Dysfunction Activity
Erectiled ysfunction (ED) is defined as the inability to achieve or maintain an erection for satisfactory sex. Prevalence of ED increases with age, and it is most commonly associated with poor cardiovascular health, psychosocial factors, hormonal disorders,r ecreational drug abuse, and adverse effects from prescribed medications. [56] Carvalho et al. investigated the effect produced by (À)-cubebin from the dried seeds of P. cubeba on the contractility and relaxation of rat aortic rings with phenylephrine to evaluate the possible mechanism involved.I tw as suggested that (À)-cubebin elicited endothelium-dependenta nd endothelium-independent vascular relaxation in rat aorta mediated by the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling pathway without prostanoid participation. [57] 3.2.7. Antibacterial Activity
In 2016, Rezende et al. studied the antibacterial activity of (À)-cubebin and its semisynthetic derivatives. Evaluation of the antibacteriala ctivityw as performedb yu sing theb roth microdilution techniquet od etermine them inimum inhibitory concentrationa nd them inimum bactericidal concentrationa gainst Porphyromonas gingivalis, Prevotella nigrescens, Actinomycesn aeslundii, Bacteroidesf ragilis,a nd Fusobacteriumn ucleatum. In this study, it wasp ossiblet oo btainr elevantd atac oncerning ther elationship betweens tructure anda ntimicrobial activity for( À)-cubebina nd otherl ignand erivativesa gainstm icroorganisms that cause root-canal infections.T his study allowed determination of which substituent groups were important to maintain or increaset he antimicrobial activity of these compounds. [29] 
Drug-Delivery Studies
In 2012, Saraiva et al. began as tudy on the encapsulation of the lignan cubebin in microparticulate polymers, as poly(d,llactide-co-glycolide), for drug delivery.T he microparticles were able to sustain the release of the drug for ac onsiderable period of time;t his allowed for ar eduction in the required frequencyo fa dministration, which increased patient compliance, avoided plasmatic fluctuations, decreaseds ide effects, and facilitated dosagea dministration. [58] 4. Hinokinin (À)-Hinokinin, ad ibenzylbutyrolactone lignan (Figure 7) , is the oxidizedf orm of the cubebin lactols and is found to accumulate in significant quantitiesi ne xtracts of P. cubeba. Furthermore,( À)-hinokinin has been reported to exhibit potent biological activities such as trypanosomicidal activity, [7, 35, 52, 59 antiinflammatory activity, [12, 31, 50, 60] and analgesic effects. [3, 7, 61] 4.1. Synthetic ApproachesDescribed
Biosynthetic Pathways
In 2008, Bayindir et al. isolated (À)-hinokinin from callus cultures of Linum corymbulosum and proposed two possible hypothetical pathways for the biosynthesis of (À)-hinokinin starting from (+ +)-pinoresinol(Scheme 3). [10, 62] ChemistryOpen 2018, 7,180 -191 www.chemistryopen.org 2018 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim
In the first pathway,( + +)-pinoresinol is reduced to (À)-secoisolariciresinolb yap inoresinollariciresinol reductase( PLR). Then, (À)-matairesinoli sf ormed by secoisolariciresinold ehydrogenase, and (À)-hinokinin is synthesized by the formation of the methylenedioxy bridges. [62] In the second pathway,t he methylenedioxy bridges are formed directly on (+ +)-pinoresinol by piperitol-sesamin synthase to give (+ +)-sesamin and may be converted into (À)-dihydrocubebin and hinokinin. By the isolation of the PLR, (À)-hinokininc ould be formed by as ecoisolariciresinold ehydrogenase-like enzyme. [62, 63] 
Chemical Synthesis
Total Synthesis of (À)-Hinokinin
In 2015, Zhou et al. outlinedt he total synthesis of the lignan (À)-hinokinin (12)i ne ight steps. The synthesis is based on a three-step cascade reaction involving ah ighly stereoselective Michael addition, anion-oxidative hydroxylation, and oxygenanion cyclization to construct the pivotal butyrolactonimidate (Scheme 6). [64] The carbanion of optically pure sulfoxide 35 reacted with unsaturated malonate 36 in ah ighly enantio-and diastereoselective mannert of orm the essential stereochemical centers. Oxidation of the malonate species permitted formation of iminolactone 37.A cidolysis by using trifluoroacetic acid (TFA) afforded lactone 38.M onodecarboxylation followed by surprisingly chemoselective reduction of the remaining ester group afforded primary alcohol 39,w hich underwent free-radicalmediated reduction of the carbonyl group by using am etal catalystt og ive 40.O xidation of 40 with the use of pyridinium chlorochromate (PCC) gave the target product, (À)-hinokinin.
Synthesis of (À)-Hinokinin by Oxidation of (À)-Cubebin
In 2008, Andrade et al. obtainede xcellent results upon using catalysts based on Fe-porphyrins (Scheme7)a nd differentr eoxidants. The conversion of (À)-cubebin into (À)-hinokinin was of the order of 100 %. This oxidation of (À)-cubebin gave better results than oxidation by more toxic heavy-metal-based oxidants such as PCC. [36] 
Biotransformation of (À)-Cubebin into (À)-Hinokinin
In 2017, Arruda et al. reported studies on the biotransformation of (À)-cubebinb yt he filamentous fungi Aspergillus terreus and Aspergillus niger is an efficient bioprocess to obtain( À)-hinokinin (12)a nd (À)-parabenzlactone (40) ( Figure 8) . [65] The advantage was the use of reagents and/or solvents that were less toxic and/or less polluting than those used in the synthesis with PCC. The biotransformationo f( À)-cubebinb yt wo Aspergillus speciesw as performed, and av alidated and reliable reverse-phase HPLC analytical method was developed to quantify the products in fungal extracts. [65] 
AsymmetricS ynthesis of (+ +)-Hinokinin
In 2007, Endersand Milovanovic published the first asymmetric synthesis of (+ +)-hinokinin (34)b yu sing asymmetricn ucleophil- Figure 7 . Possible chemical structureso fh inokinin. Enantiomer pairs for cis-32/33 and trans-hinokinin (12/34). [10] (À)-Hinokinin (12) [36] and (+ +)-Hinokinin (34). [65] Scheme6.Synthesis of (À)-hinokinin.
[63] LiHMDS = lithium hexamethyldisilazide.
Scheme7.Preparation of (À)-hinokinin (12)b yo xidation of (À)-cubebin (1) catalyzed by Fe-porphyrin. [36] ChemistryOpen 2018, 7,180 -191 www.chemistryopen.org 2018 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim ic acylation methodology.U sing the methodology indicated in Scheme 8, aminonitrile (S,S,R,R,S)-42 was obtained in quantitative yield with high diastereomeric purity,f rom whichi tw as possible to provide enantiopure trans-2,3-disubstituted g-butyrolactone (S,S)-45 with excellent asymmetric induction. Reductiono ft he ketone to the correspondinga lcohola sa ne pimeric mixture and then hydrogenolysis afforded( + +)-hinokinin (34)w ith excellent stereoisomeric purity. [66] 4.2. Biological Activities
Cytotoxic Activity
The cytotoxicity of (À)-hinokinin has been investigated against differentc ancerl ines by several authors. Compared to (À)-cubebin, (À)-hinokinin presents better results. [2, 67, 68] In 2010, Pusztai et al. isolated (À)-hinokinin (12)f rom the stem bark of the African tree Pycnanthus angolensis (Welw.) Warb. (Myristicaceae)a nd evaluatedi ts potentiala sacancer chemopreventative agent by its ability to inhibit HCMV early (IE) antigen expression in human lung adenocarcinoma (A549) cells. [67] Human cytomegalovirus (HCMV) was used in amodified in vitro model to evaluate the potential antitumor-promoting effects of this lignan on human lung cancerc ells. Concentrations of 40.72 mgmL À1 caused 50 %i nhibition of growth (ID 50 ) of A549 lung cancerc ells. Significant results were obtained with hinokinin to reduce the IE gene expression of HCMV in a dose-dependent manner. [67] 
Anti-inflammatory Activity
In 2013, Desai et al. isolated( À)-hinokinin from the extracts of Aristolochia indica L. by using an efficient preparative HPLC method, [69] and it was tested forits anti-inflammatory potential. The authors reported the anti-inflammatory effects of hinokinin against IL-6 [IC 50 = (20.5 AE 0.5) mm]a nd TNFa [IC 50 = (77.5 AE 27.5) mm]. Both IL-6 and TNFa are key regulators of inflammation and are implicated in several diseases such as rheumatoid arthritisand colitis. [69] In 2017, Lima et al. isolated (À)-cubebin from the seeds of Piper cubeba and obtained (À)-hinokinin by oxidation with PCC. Using paw edema as the experimental model and different chemical mediators (prostaglandin and dextran), it was observedt hat both derivatives were active in comparison with both negative (5 %T ween 80 in saline) and positive (indomethacin) controls. The reduction in prostaglandin-induced edemaw ith (À)-hinokinin was 59.2 %. [12] 
Antitumor Activity
In 2016, Cunha et al. evaluated the ability of (À)-hinokinin (12) to modulate the antiproliferativee ffects of doxorubicin (DOX) in tumoral (MCF-7 and SKBR-3) and normal (MCF-10 A) breast cell lines. [68] Treatment with (À)-hinokinin did not affect cellular proliferation or contribute to the antiproliferative effectso f doxorubicin in MCF-10A cells. After 24 and 48 ho ft reatment with (À)-hinokinin, MCF-7 and SKBR-3 were accumulated in G2/M,and if combined with doxorubicin, (À)-hinokinin contributed to the antiproliferativee ffects of this chemotherapeutic by modulating the cyclin-dependentk inase inhibitor.T he clinical implications of the selectiveness of (À)-hinokinin if associated with subcytotoxic concentrations of DOX may be furtheri nvestigated to reduce the sideeffects. [68] 4.2.4. Antiparasitic Activity (À)-Hinokinin (12), in later years, has been studied as an interesting antitripanosomal compound. [52, 53, 58, 70, 71] In 2005, De Souza et al. initiated as tudy by using hinokinin in vitro against free amastigote forms of the Ys train of T. cruzi. The results were encouraging, as an IC 50 value of 0.7 mm wasm easured compared to an IC 50 value of 0.8 mm for benznidazole. [35] In 2013, Esperandim et al. reported studies on infections by Trypanosoma cruzi. This study has already been referenced in Section3.2.3. for the lignan (À)-cubebin. [53] The authors described as tudy criterion in whicha nimalsw ith acute parasitemia were investigated by tissue morphometric analysis.Asignificant parasitemia reduction was observed in the groups of animalstreated with (À)-cubebin (1)o r( À)-hinokin (12)b yoral (12)and (7's)-parabenzolactone (41). [64] Scheme8.Asymmetric synthesis of (+ +)-hinokinin. [65] ChemistryOpen 2018, 7,180 -191 www.chemistryopen.org . [72] (À)-Hinokinin was moderately active against M. tuberculosis,w ith am inimum inhibitory concentration of 62.5 mgmL
À1
.T hese are promising results that are important in the search for biologically active naturalp roducts, as they highlight the fact that new approaches for the prevention, treatment, and cure of tuberculosis are extremely important. [72, 73] 
Drug-Delivery Studies
In 2010, Saraiva et al. loaded (À)-hinokinin into PLGA microparticles for the treatment of Chagas disease. [59] PLGA polymers have generated great interest due to their excellent biocompatibility and biodegradability.I nt his study,t he microparticles formed presentedanarrow size distribution and am ean diameter of 0.862 mmw ith ap olydispersity index of 0.072 nm. The encapsulation efficiency of (À)-hinokinin-loaded microparticles with ad rug-to-polymer weightr atio of 1:10 was (72.46 AE 2.92) %. [59] In 2013, Timple et al. examined the lignan (À)-hinokinin with severald ifferent human neurotransmitter transporters for potential use in drug therapy. [74] Using in vitro pharmacological assays,(À)-hinokinin selectively inhibited the humand opamine and norepinephrine transporters in an oncompetitive manner, possibly mediated by binding to an ovel site within the transporters, and displayed low affinity for the serotonin transporter. [74] 
Conclusions
Piper cubeba hasb een widely studied by several research groups.I ti sagenus that can be found in all continentsw ithin severals pecies. The main compounds isolated from two species have shown potentialt ob ecome new molecules in their natural and semisynthetic forms for therapeutic applications. Researchers have been studying cubebin and its derivatives obtainedb ys emisynthesis and have found great therapeutic perspectives. Many variations of the aromatic ring substituents of cubebin are possible, and these could be tailoreda ccording to the desired biological activity.
Cubebin (1)h as proveni nvivo efficacy in mosto ft he activities described in this article. Hinokinin is as ubstance that has demonstrated high analgesic, anti-inflammatory,a ntimutagenic, chemopreventive and antitumorala ctivities;i th as proven activity against trypanosoma cruzi and antibacterial activity against oral pathogens. Hinokinin certainly deserves attention and has great therapeutic potential. Considering the patents on the use of cubebin andt he conductiono fn onclinical and clinicalt rials, in af ew years it should certainly be possible to have an ew drug based upon these natural products studies.
Recently,t he total syntheseso f( À)-cis-cubebin,( À)-bicubebin A ( 20) , (À)-bicubebin B ( 26) , and (+ +)-bicubebin C( 27)h ave confirmed their structures and absolutes tereochemistry.T he proposed structure of an isolated naturalp roduct ascribed to the cis-cubebin structure has been shown to be incorrect and is in fact (À)-bicubebin B.
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